A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
In this analysis of the switch between oADA and bADA, no differences were found in disease activity, functional capacity, or radiographic progression. Ultrasonography indicated improvement of PD findings.
Authors
- Rodrigo Nicolás Garcia Salinas (ORCID: https://orcid.org/0000-0002-5928-1092)
- Santiago Ruta (ORCID: https://orcid.org/0000-0002-4071-7300)
- Álvaro Ruta (ORCID: https://orcid.org/0009-0009-0637-7785)
- Sebastián Magri (ORCID: https://orcid.org/0009-0005-5433-2726)
Institutions
- Hospital Italiano La Plata (AR)
Publication Details
- Journal
- Reumatismo
- Published
- 2025-05-08
- DOI
- https://doi.org/10.4081/reumatismo.2025.1748
- Primary Topic
- Biosimilars and Bioanalytical Methods
- Type
- article
- Field-Weighted Citation Impact
- 0.00